Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $50.00 Price Target at Barclays

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective cut by Barclays from $81.00 to $50.00 in a report issued on Monday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

RARE has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, September 9th. TD Cowen decreased their price objective on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Truist Financial dropped their target price on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Wells Fargo & Company initiated coverage on Ultragenyx Pharmaceutical in a research note on Monday, October 20th. They set an “overweight” rating and a $65.00 price target on the stock. Finally, Canaccord Genuity Group lowered their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $80.23.

Ultragenyx Pharmaceutical Stock Down 2.4%

Shares of NASDAQ:RARE opened at $32.78 on Monday. The company has a 50-day moving average price of $31.83 and a 200 day moving average price of $32.43. Ultragenyx Pharmaceutical has a 52 week low of $25.81 and a 52 week high of $50.00. The company has a market cap of $3.16 billion, a P/E ratio of -5.93 and a beta of 0.30.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The business had revenue of $159.93 million for the quarter, compared to analysts’ expectations of $167.42 million. During the same period last year, the company posted ($1.40) earnings per share. The business’s quarterly revenue was up 14.6% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Analysts expect that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of the firm’s stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $31.51, for a total value of $250,252.42. Following the sale, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at approximately $3,095,132.77. This trade represents a 7.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,450 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares of the company’s stock, valued at $2,283,857.07. This trade represents a 3.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 10,456 shares of company stock valued at $328,486 over the last quarter. 5.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently bought and sold shares of the stock. Danske Bank A S purchased a new position in Ultragenyx Pharmaceutical during the third quarter worth approximately $39,000. Jacobs Levy Equity Management Inc. raised its position in shares of Ultragenyx Pharmaceutical by 614.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock worth $65,205,000 after buying an additional 1,864,164 shares during the period. CANADA LIFE ASSURANCE Co grew its position in Ultragenyx Pharmaceutical by 2.0% during the third quarter. CANADA LIFE ASSURANCE Co now owns 26,932 shares of the biopharmaceutical company’s stock valued at $817,000 after acquiring an additional 534 shares during the period. Voloridge Investment Management LLC acquired a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $14,516,000. Finally, Vestal Point Capital LP purchased a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $22,560,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.